| Original cohorta | PS-matched cohorta | ||||||
---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
OR (95% CI) | p value | aOR (95% CI) | p value | OR (95% CI) | p value | aOR (95% CI) | p value | |
Age | 1.00 (0.99–1.01) | 0.554 |  |  | 0.98 (0.97–1) | 0.041 | 0.99 (0.97–1.01) | 0.175 |
Male | 1.15 (0.79–1.67) | 0.479 |  |  | 0.97 (0.54–1.75) | 0.916 |  |  |
BMI | 0.99 (0.96–1.03) | 0.674 |  |  | 0.96 (0.91–1.02) | 0.211 |  |  |
CRAB | 1.12 (0.72–1.76) | 0.607 |  |  | 0.93 (0.48–1.81) | 0.823 |  |  |
Medical ICU | 1.53 (1.08–2.17) | 0.017 | 1.58 (1.06–2.35) | 0.024 | 0.9 (0.52–1.57) | 0.711 |  |  |
Smoking | 1.12 (0.73–1.71) | 0.615 |  |  | 0.99 (0.56–1.76) | 0.970 |  |  |
Malignancies | 0.85 (0.52–1.39) | 0.519 |  |  | 1.07 (0.51–2.25) | 0.855 |  |  |
Renal insufficiency | 0.93 (0.60–1.43) | 0.727 |  |  | 1.72 (0.87–3.4) | 0.118 |  |  |
Chronic lung diseases | 0.70 (0.48–1.01) | 0.054 | 1.07 (0.66–1.72) | 0.790 | 1.09 (0.55–2.16) | 0.807 |  |  |
Diabetes | 1.05 (1.02–1.08) |  < 0.001 | 0.76 (0.51–1.14) | 0.185 | 0.66 (0.36–1.19) | 0.162 |  |  |
APACHE II score | 1.17 (1.11–1.23) |  < 0.001 | 1.03 (1.00–1.06) | 0.056 | 1.01 (0.96–1.05) | 0.769 |  |  |
SOFA scorec | 2.51 (1.66–3.79) |  < 0.001 | 1.12 (1.05–1.19) | 0.001 | 1.19 (1.09–1.29) | 0.000 | 1.16 (1.05–1.28) | 0.004 |
PF ratio ≤ 200c | 2.30 (1.40–3.78) | 0.001 | 1.83 (1.13–2.94) | 0.013 | 2.27 (1.2–4.3) | 0.012 | 1.57 (0.74–3.33) | 0.242 |
Septic shock c | 1.19 (0.73–1.96) | 0.482 |  |  | 1.78 (0.69–4.57) | 0.234 |  |  |
Albumin ≤ 3 mg/dL | 1.48 (1.05–2.09) | 0.025 | 1.4 (0.95–2.05) | 0.088 | 1.39 (0.81–2.4) | 0.234 |  |  |
Inappropriate empiric therapy | 1.54 (1.01–2.36) | 0.047 | 1.64 (1.04–2.59) | 0.033 | 1.77 (0.90–3.50) | 0.098 | 2.01 (0.98–4.14) | 0.058 |
Substitutive nebulized colistind | 0.45 (0.32–0.65) |  < 0.001 | 0.45 (0.30–0.67) |  < 0.001 | 0.5 (0.29–0.87) | 0.013 | 0.48 (0.27–0.87) | 0.015 |